The company reported a loss of 13 cents a share, compared to a loss of 26 cents a share in the same period one year earlier. This narrowly beat the consensus estimate of a loss of 14 cents a share by a penny. Revenue increased 20.3% year over year to $46.3 million, which beat the consensus estimate of $46.06 million.
Sequenom also disclosed in a regulatory filing that Chief Medical Officer Allan Bombard told the company he would retire from Sequenom as of its next annual stockholders' meeting on June 10.
Must Read: Warren Buffett's 10 Favorite Growth StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The stock was up 13.07% to $3.02 at noon. STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.